Czech; Joerg

Patent Applications and Registrations

Patent applications and USPTO patent grants for Czech; Joerg.The latest application filed is for "pyrrole derivatives as p2y12 antagonists".

Company Profile

0.12.8

Czech; Joerg - Marburg N/A DE
Czech; Joerg - Frankfurt am Main DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Quinoline-carboxamide derivatives as P2Y12 antagonists Grant 8,669,266 - Nazare , et al. March 11, 2	2014-03-11
Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy Grant 8,552,159 - Bosslet , et al. October 8, 2	2013-10-08
Use of PAK inhibitor for the treatment of a joint disease Grant 8,187,828 - Barradeau , et al. May 29, 2	2012-05-29
Pyrrole derivatives as P2Y12 antagonists Grant 7,910,576 - Klingler , et al. March 22, 2	2011-03-22
Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders Grant 7,892,744 - Kozian , et al. February 22, 2	2011-02-22
Imino-imidazo-pyridine derivatives having antithrombotic activity Grant 7,863,269 - Heinelt , et al. January 4, 2	2011-01-04
Pyrrole Derivatives As P2y12 Antagonists App 20100226918 - KLINGLER; Otmar ; et al.	2010-09-09
Analysis And Use Of Par1 Polymorphisms For Evaluating The Risk Of Cardiovascular Disease App 20100221714 - KOZIAN; Detlef ; et al.	2010-09-02
Quinoline-carboxamide Derivatives As P2y12 Antagonists App 20100135999 - Nazare; Marc ; et al.	2010-06-03
Imino-imidazo-pyridine Derivatives Having Antithrombotic Activity App 20090192150 - HEINELT; Uwe ; et al.	2009-07-30
Use Of Pak Inhibitor For The Treatment Of A Joint Disease App 20090104279 - BARRADEAU; Sebastian ; et al.	2009-04-23
Use of PAK inhibitor for the treatment of a joint disease Grant 7,364,887 - Barradeau , et al. April 29, 2	2008-04-29
Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli Grant 7,314,753 - Opper , et al. January 1, 2	2008-01-01
Use of PAK inhibitor for the treatment of a joint disease App 20050037965 - Barradeau, Sebastian ; et al.	2005-02-17
Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders App 20050019795 - Kozian, Detlef ; et al.	2005-01-27
Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy App 20040202646 - Bosslet, Klaus ; et al.	2004-10-14
Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli Grant 6,602,688 - Opper , et al. August 5, 2	2003-08-05
Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli Grant 6,008,023 - Opper , et al. December 28, 1	1999-12-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.